Axon Enterprise, Inc. (NASDAQ:AXON) Short Interest Down 12.4% in November

Axon Enterprise, Inc. (NASDAQ:AXON) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 2,260,000 shares, a decrease of 12.4% from the November 15th total of 2,580,000 shares. Based on an average daily volume of 711,500 shares, the short-interest ratio is presently 3.2 days.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Julie A. Cullivan sold 1,261 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total value of $860,077.66. Following the completion of the transaction, the director now owns 2,392 shares in the company, valued at $1,631,487.52. This represents a 34.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeri Williams sold 110 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $400.00, for a total value of $44,000.00. Following the completion of the sale, the director now directly owns 1,934 shares of the company’s stock, valued at $773,600. The trade was a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 99,590 shares of company stock valued at $49,176,907. Insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Axon Enterprise by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock valued at $710,103,000 after acquiring an additional 35,320 shares during the period. Westfield Capital Management Co. LP lifted its stake in shares of Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after purchasing an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC grew its stake in shares of Axon Enterprise by 13.9% in the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after buying an additional 83,265 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Axon Enterprise by 1.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after buying an additional 9,090 shares during the period. Finally, Groupama Asset Managment acquired a new position in Axon Enterprise during the 3rd quarter worth approximately $200,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on AXON shares. Needham & Company LLC upped their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Friday, November 8th. JMP Securities boosted their price objective on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research note on Thursday, October 31st. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $500.00 to $700.00 in a report on Tuesday, December 3rd. Northland Securities increased their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, The Goldman Sachs Group boosted their target price on Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $488.67.

Axon Enterprise Trading Up 1.3 %

NASDAQ AXON traded up $8.50 during trading hours on Friday, hitting $644.91. 557,664 shares of the company’s stock were exchanged, compared to its average volume of 792,830. The business’s 50 day moving average is $539.52 and its 200-day moving average is $405.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise has a 12-month low of $241.72 and a 12-month high of $698.67. The firm has a market capitalization of $49.17 billion, a P/E ratio of 166.64, a price-to-earnings-growth ratio of 14.19 and a beta of 1.01.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.